Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 1,339 Shares of Stock

by · The Markets Daily

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Derek Maetzold sold 1,339 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $40.10, for a total transaction of $53,693.90. Following the completion of the transaction, the insider directly owned 29,513 shares of the company’s stock, valued at $1,183,471.30. This trade represents a 4.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock traded up $0.54 during midday trading on Wednesday, hitting $40.61. 274,232 shares of the company traded hands, compared to its average volume of 398,331. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -90.24 and a beta of 1.06. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47. The firm’s fifty day moving average price is $36.73 and its 200-day moving average price is $26.50. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $42.17.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. The business had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. As a group, sell-side analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CSTL. Guggenheim upped their target price on Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings restated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. BTIG Research raised their price objective on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 12th. Canaccord Genuity Group boosted their target price on shares of Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Finally, Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 2nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Castle Biosciences presently has an average rating of “Moderate Buy” and an average target price of $43.17.

Read Our Latest Report on Castle Biosciences

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Schroder Investment Management Group raised its position in shares of Castle Biosciences by 8.6% in the 2nd quarter. Schroder Investment Management Group now owns 648,572 shares of the company’s stock worth $13,198,000 after acquiring an additional 51,483 shares in the last quarter. Advisors Capital Management LLC grew its stake in Castle Biosciences by 21.9% during the second quarter. Advisors Capital Management LLC now owns 245,867 shares of the company’s stock worth $5,021,000 after purchasing an additional 44,180 shares during the period. Squarepoint Ops LLC increased its holdings in Castle Biosciences by 29.1% in the second quarter. Squarepoint Ops LLC now owns 125,719 shares of the company’s stock worth $2,567,000 after purchasing an additional 28,359 shares in the last quarter. Caxton Associates LLP acquired a new position in Castle Biosciences in the first quarter valued at approximately $329,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Castle Biosciences by 6.2% during the 2nd quarter. Geode Capital Management LLC now owns 689,926 shares of the company’s stock worth $14,090,000 after buying an additional 40,073 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.

Further Reading